Calithera Biosciences is a clinical-stage pharmaceutical company focused on discovering and developing novel small molecule drugs directed against tumor metabolism and tumor immunology targets for the treatment of cancer. The Company's lead product candidate in tumor metabolism, CB-839, is an internally discovered, first-in-class inhibitor of glutaminase, a critical enzyme in tumor metabolism. Calithera is currently evaluating CB-839 in three Phase 1 clinical trials in solid and hematological tumors.

In tumor immunology, the Company's lead preclinical program is directed at developing inhibitors of the enzyme arginase and may provide a first-in-class therapeutic agent for this novel target. Calithera Biosciences's ongoing research efforts are focused on discovering additional product candidates against novel tumor metabolism and immunology targets.

Type
Public
HQ
South San Francisco, US
Founded
2010
Size (employees)
50 (est)
Calithera Biosciences was founded in 2010 and is headquartered in South San Francisco, US
Report incorrect company information

Key People/Management at Calithera Biosciences

Mark Bennett

Mark Bennett

Senior Vice President of Research
Curtis Hecht

Curtis Hecht

Senior Vice President of Business and Corporate Development
Christopher Molineaux

Christopher Molineaux

Senior Vice President of Development
Keith Orford

Keith Orford

Senior Vice President of Clinical Development
Sumita Ray

Sumita Ray

Senior Vice President, General Counsel and Chief Compliance Officer
Eric Sjogren

Eric Sjogren

Senior Vice President of Drug Discovery
Show more

Calithera Biosciences Office Locations

Calithera Biosciences has an office in South San Francisco
South San Francisco, US (HQ)
200 343 Oyster Point Blvd
Show all (1)
Report incorrect company information

Calithera Biosciences Financials and Metrics

Calithera Biosciences Financials

Calithera Biosciences's revenue was reported to be $25.96 m in FY, 2017
USD

Revenue (Q1, 2018)

5.2 m

Net income (Q1, 2018)

(13.2 m)

EBIT (Q1, 2018)

(13.8 m)

Market capitalization (21-May-2018)

186.4 m

Closing share price (21-May-2018)

5.2

Cash (31-Mar-2018)

54.8 m
Calithera Biosciences's current market capitalization is $186.4 m.
Annual
USDFY, 2014FY, 2015FY, 2016FY, 2017

Revenue

26 m

General and administrative expense

5.4 m9.1 m10.6 m12.5 m

R&D expense

16.4 m23.7 m27.7 m43.1 m

Operating expense total

21.7 m32.8 m38.3 m55.6 m
Quarterly
USDQ2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q1, 2018

Revenue

4.2 m7.3 m5.2 m

General and administrative expense

2.3 m2.2 m2.6 m2.7 m2.3 m3.3 m2.8 m3.5 m

R&D expense

5.5 m6.8 m7.1 m7.8 m6.3 m6.6 m10.1 m15.5 m

Operating expense total

7.9 m9 m9.7 m10.4 m8.6 m9.9 m13 m19 m
Annual
USDFY, 2014FY, 2015FY, 2016FY, 2017

Cash

102 m6.1 m10.6 m48.5 m

Inventories

1.9 m2.6 m1.8 m

Current Assets

103.9 m72.5 m53.6 m167.7 m

PP&E

861 k931 k899 k1.8 m
Quarterly
USDQ2, 2017Q1, 2018

Cash

58 m54.8 m

Current Assets

170.4 m155.8 m

PP&E

977 k1.7 m

Total Assets

214.1 m178.6 m
Annual
USDFY, 2014FY, 2015FY, 2016FY, 2017

Net Income

(21.7 m)(32.6 m)(38 m)(27.8 m)

Depreciation and Amortization

361 k404 k297 k365 k

Inventories

(1.5 m)(673 k)787 k

Accounts Payable

543 k(131 k)(28 k)674 k
Quarterly
USDQ3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q1, 2018

Net Income

(7.8 m)(8.9 m)(9.6 m)(10.4 m)(8.5 m)(5.6 m)(13.2 m)

Depreciation and Amortization

124 k

Accounts Payable

879 k559 k923 k565 k1.1 m1.4 m1.3 m600 k1.1 m

Cash From Operating Activities

(15 m)
USDY, 2018

Financial Leverage

1.2 x
Show all financial metrics

Calithera Biosciences Operating Metrics

FY, 2016

Phase 1/2 Trials Products

1

Phase I Trials Products

1
Show all operating metrics
Report incorrect company information

Calithera Biosciences News and Updates

Report incorrect company information